Latest From Ivenix Inc.
Marc Jones is taking on the dual role of chief operating officer and chief financial officer at UK point-of-care diagnostics firm Atlas Genetics.
Medtech companies brought in $2.3 billion in financing in Q1 2017, a slight decrease from Q4 2016; device M&A deals totaled $5.8 billion, a sharp decline from the prior quarter, but there were some billion-dollar deals. Q1 diagnostics financings – totaling $1.2 billion (thanks to a $900 million Series B round by cancer diagnostics company Grail) – showed a significant increase over the preceding quarter, as did the Q1 M&As at $700 million versus the previous $87 million.
Ivenix Inc. said it has closed on the first tranche of $50m in equity financing, which will put the Amesbury, Massachusetts-based infusion-pump startup on track to pursue FDA approval for its Ivenix Infusion System.
While infusion pumps are vital to patient care and used in abundance in hospitals, they are also associated with numerous errors. One of the keys to addressing this problem lies in improving the devices’ interoperability with hospital IT systems, and as those changes are starting to materialize, so are opportunities for new players in this space.
- Infusion Therapy Equipment and Supplies
- Therapeutic Areas
- Fluidnet Corp.
- North America
- Parent & Subsidiaries
- Ivenix Inc.
- Senior Management
Stuart A Randle, CEO & President
Jesse E Ambrosina, Co-CTO
George W Gray, Co-CTO
Mark E Casey, VP, Mfg.
John J Sokolowski, VP, Regulatory & QA
- Contact Info
Phone: (978) 792-5000
21 Water St.
Amesbury, MA 01913
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.